8-K - Denali Therapeutics Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Denali Therapeutics regains full rights to DNL593 after Takeda terminates their collaboration agreement for strategic reasons, with Phase 1/2 data expected by end of 2026.

Key Takeaways

1Takeda terminated the DNL593 collaboration agreement effective 60 days from notice; decision driven by strategic considerations, not efficacy or safety.

2All rights to the DNL593 program and its intellectual property portfolio revert to Denali upon termination.

3Denali has no further financial obligations to Takeda following the termination.

4Denali plans to continue clinical development independently and report Phase 1/2 results by end of 2026.

5Interim Phase 1/2 data showed dose-dependent increases in cerebrospinal fluid progranulin; DNL593 was generally well tolerated.

Current Report Details

Event Type

Material Agreement

Exhibits Only

Disclosure

Mandatory

Variant

8-K

Items Reported

1.02

Termination of a Material Definitive Agreement. On April 3, 2026, Denali Therapeutics Inc. (“Denali”) received written notice from Takeda Pharmaceutical Company

Material Agreement

9.01

Financial Statements and Exhibits. (d) Exhibits The information furnished in this Item 9.01 (including Exhibit 99.1) shall not be deemed to be “filed” for purpo

Exhibits Only

Source Document

Transaction Details

Material Agreement

Agreement: Collaboration Agreement
Parties: Denali Therapeutics Inc., Takeda Pharmaceutical Company Limited

•Agreement dated January 3, 2018 to co-develop and co-commercialize DNL593 (PTV:PGRN).
•Termination notice received April 3, 2026; effective 60 days following notice date.
•Reason for termination: Strategic considerations; not related to efficacy or safety data.
•All rights in the DNL593 program revert to Denali upon termination.
•Denali has no further financial obligations to Takeda following termination.

Exhibits (2)

8-K

99.1

EX-99.1